Purus Wealth Management LLC Takes $212,000 Position in Pfizer Inc. $PFE

Purus Wealth Management LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 8,739 shares of the biopharmaceutical company’s stock, valued at approximately $212,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Bedell Frazier Investment Counselling LLC boosted its stake in shares of Pfizer by 30.6% during the 2nd quarter. Bedell Frazier Investment Counselling LLC now owns 29,780 shares of the biopharmaceutical company’s stock valued at $722,000 after buying an additional 6,970 shares during the last quarter. Portside Wealth Group LLC raised its holdings in Pfizer by 1.4% in the second quarter. Portside Wealth Group LLC now owns 68,758 shares of the biopharmaceutical company’s stock valued at $1,667,000 after acquiring an additional 925 shares in the last quarter. United Advisor Group LLC raised its holdings in Pfizer by 22.8% in the second quarter. United Advisor Group LLC now owns 15,047 shares of the biopharmaceutical company’s stock valued at $365,000 after acquiring an additional 2,794 shares in the last quarter. Vanguard Group Inc. boosted its stake in Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after acquiring an additional 10,198,330 shares during the last quarter. Finally, Pinnacle Wealth Planning Services Inc. grew its holdings in Pfizer by 17.4% during the 2nd quarter. Pinnacle Wealth Planning Services Inc. now owns 24,875 shares of the biopharmaceutical company’s stock worth $603,000 after acquiring an additional 3,686 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent research reports. Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Finally, UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer Stock Performance

Shares of PFE opened at $25.06 on Tuesday. The company has a 50-day moving average of $24.81 and a two-hundred day moving average of $24.45. The stock has a market cap of $142.47 billion, a price-to-earnings ratio of 13.33, a PEG ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.